I don't know what he's said about Regal (cba looking it up) and I don't know if you are alluding to this or not, but a couple of years ago Phil King of Regal Funds publicly stated his view that CUV was, amongst a few others, one of the most overvalued biotechs out there. He cited Australians as not being very good at valuing drug companies. Is there an echo in the room?
https://www.copyright link/markets/equity-markets/bubble-in-biotech-stocks-troubles-investors-20191125-p53dsj
Ann: Change of Director's Interest Notice, page-28
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.66 |
Change
-0.080(0.54%) |
Mkt cap ! $735.1M | |||
| Open | High | Low | Value | Volume |
| $14.74 | $14.77 | $14.50 | $366.8K | 25.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 238 | $14.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.67 | 54 | 3 |
View Market Depth
| Last trade - 14.13pm 30/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |